Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era
- 1 September 1996
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 78 (6) , 32-41
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Cholesterol Lowering and the Use of Healthcare ResourcesCirculation, 1996
- Task force 6. Cost effectiveness of assessment and management of risk factorsJACC, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- The Cost-effectiveness of HMG-CoA Reductase Inhibitors to Prevent Coronary Heart DiseaseJAMA, 1995
- Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)JAMA, 1993
- The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)Archives of internal medicine (1960), 1993
- Reducing High Blood Cholesterol Level With DrugsJAMA, 1990
- Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in The NetherlandsThe American Journal of Cardiology, 1990
- Cutting Into CholesterolJAMA, 1988
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984